A Study of CSPCHA131 in Patients With Advanced Solid Tumor
The study was designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of CSPCHA131 alone or plus chemotherapy in patients with advanced solid tumors.
Advanced Solid Tumors
DRUG: CSPCHA131
Maximum tolerated dose (MTD) and incidence of dose limiting toxicity (DLT) within the first cycle at each dose level., Time Frame: 28 days|Incidence of adverse events (AEs) and serious adverse events throughout the trial;, from enrollment to the end of the trial (2 years)
Objective response rate (ORR) defined by RECIST Criteria Version 1.1;, ORR is defined as the proportion of patients who achieve complete response (CR) or partial response (PR)., from enrollment to the end of the trial (2 years)|Progression free survival (PFS) defined by RECIST Criteria Version 1.1;, PFS is defined as the time from the start of treatment until disease progression or death from any cause, whichever is earlier., from enrollment to the end of the trial (2 years)|AUC0-t, PK parameter: AUC0-t, 28 days|AUC0-∞, PK parameter: AUC0-∞, 28 days|Cmax, PK parameter: Cmax, 28 days|Css_max, PK parameter: Css_max, 28 days|Css_min, PK parameter: Css_min, 28 days|DF, PK parameter: DF, 28 days|Ke, PK parameter: Ke, 28 days|Tmax, PK parameter: Tmax, 28 days|Vz, PK parameter: Vz, 28 days|T1/2, PK parameter: T1/2, 28 days|CL, PK parameter: CL, 28 days
This is a dose escalation and expansion study with the aim to evaluate and characterize the tolerability and safety profile of CSPCHA131 alone (Stage I) or plus chemotherapy (Stage II) in patients with advanced solid tumors.